The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

doi:10.1007/s002280050219

Back to search

Article

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

European journal of clinical pharmacology - 1 Jan 1997

Christensen P M, Gøtzsche P C, Brøsen K

Abstract excerpt

OBJECTIVE: To examine the association between the sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer. METHOD: Meta-analysis of case-control studies using a random effects model. The "Main outcome measure" was the odds ratio for the risk of lung cancer, using extens...

Topics

Cytochrome P-450 CYP2D6
Debrisoquin
Disease Susceptibility
Genotype
Humans
Lung Neoplasms
Odds Ratio
Oxidation-Reduction
Phenotype
Polymorphism, Genetic
Risk Factors
Sparteine

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.